Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
暂无分享,去创建一个
Benjamin L. Ebert | Michael R. Savona | John M. Bennett | Max F. Levine | Elsa Bernard | Michael Heuser | Valeria Santini | Luca Malcovati | Eva Hellström-Lindberg | Joop H. Jansen | Shigeru Chiba | Yangyu Zhou | Pierre Fenaux | Elli Papaemmanuil | Robert P. Hasserjian | Mario Cazzola | Olivier Kosmider | Seishi Ogawa | Gunes Gundem | Monika Belickova | Peter Valent | Takayuki Ishikawa | Francesc Sole | Uwe Platzbecker | A. Viale | Alexandra G. Smith | M. Cazzola | D. Neuberg | B. Ebert | F. Solé | E. Papaemmanuil | M. Heuser | F. Thol | G. Gundem | R. Bejar | S. Ogawa | P. Greenberg | M. Voso | L. Shih | Y. Shiozawa | M. Jädersten | S. Devlin | T. Yoshizato | J. Bennett | K. Stevenson | P. Fenaux | J. Cervera | E. Hellström-Lindberg | L. Adès | P. Valent | C. Finelli | J. Jansen | U. Germing | I. Kotsianidis | M. Fontenay | Y. Nannya | Y. Miyazaki | J. Boultwood | L. Malcovati | A. Takaori-Kondo | A. Pellagatti | M. Porta | A. A. van de Loosdrecht | U. Platzbecker | V. Santini | M. D. Della Porta | S. Chiba | Yanming Zhang | N. Gattermann | V. Klimek | Minal A. Patel | M. Belickova | G. Sanz | O. Kosmider | K. Vanness | K. Bolton | Heinz Tuechler | Julie Schanz | Guillermo Sanz | Yasushi Miyazaki | Ulrich Germing | Detlef Haase | Yasuhito Nannya | Andrea Pellagatti | Jacqueline Boultwood | Lee-Yung Shih | Matteo Giovanni Della Porta | M. Follo | Y. Atsuta | José Cervera | Felicitas Thol | H. Tsurumi | Martin Jädersten | Alexandra G Smith | Akifumi Takaori-Kondo | Minal Patel | Yusuke Shiozawa | Michaela Fontenay | Yanming Zhang | R. Hasserjian | M. Savona | E. Bernard | H. Tuechler | J. Medina-Martinez | R. Saiki | M. Levine | Juan E. Arango | Yangyu Zhou | C. Cargo | D. Haase | M. Creignou | Araxe Sarian | M. Tobiasson | R. Pinheiro | F. P. Santos | J. Schanz | S. Kasahara | T. Ishikawa | T. Kiguchi | C. Polprasert | C. Ganster | Laura Palomo | Yesenia Werner | K. Menghrajani | Yoshiko Atsuta | Donna S. Neuberg | Norbert Gattermann | Carlo Finelli | Sean M. Devlin | Agnès Viale | Rafael Bejar | Tetsuichi Yoshizato | Matilde Y. Follo | Arjan A. van de Loosdrecht | Kelly L. Bolton | Peter L. Greenberg | Juan S. Medina-Martinez | Ryunosuke Saiki | Catherine A. Cargo | Maria Creignou | Araxe Sarian | Magnus Tobiasson | Ronald F. Pinheiro | Ioannis Kotsianidis | Fabio P.S. Santos | Senji Kasahara | Hisashi Tsurumi | Toru Kiguchi | Chantana Polprasert | Virginia M. Klimek | Christina Ganster | Laura Palomo | Lionel Ades | Yesenia Werner | Katelynd Vanness | Kristen E. Stevenson | Kamal Menghrajani | Maria Teresa Voso | H. Elias | L. Palomo | Harold Elias | Kamal Menghrajani
[1] Berthold Lausen,et al. Maximally selected rank statistics , 1992 .
[2] T. Jacks,et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[3] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[4] N. Socci,et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.
[5] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[6] A. Hagemeijer,et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Kitagawa,et al. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. , 1994, The American journal of pathology.
[8] Alexandra G. Smith,et al. Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort , 2018, International journal of epidemiology.
[9] Christopher A. Miller,et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2016, The New England journal of medicine.
[10] C. Cole,et al. COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.
[11] Donna Neuberg,et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies , 2019, Science.
[12] Dmitriy Sonkin,et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.
[13] Ryan L. Collins,et al. The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.
[14] A. Børresen-Dale,et al. The Life History of 21 Breast Cancers , 2012, Cell.
[15] N. Socci,et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity , 2015, Nature Biotechnology.
[16] Eva Hellström-Lindberg,et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[18] Eric Talevich,et al. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..
[19] Shicai Wang,et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer , 2018, Nucleic Acids Res..
[20] M. Ladanyi,et al. Abstract 3409: MSK-IMPACT Heme: Validation and clinical experience of a comprehensive molecular profiling platform for hematologic malignancies , 2019, Molecular and Cellular Biology / Genetics.
[21] S. Nahas,et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.
[22] Aviad Tsherniak,et al. Mutational processes shape the landscape of TP53 mutations in human cancer , 2018, Nature Genetics.
[23] P. McSweeney. Something for everyone. , 1988, Nursing times.
[24] E. Roman,et al. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15 , 2016, Cancer epidemiology.
[25] P. Campbell,et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms , 2018, The New England journal of medicine.
[26] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[27] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[28] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[29] Ryan L. Collins,et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes , 2019, bioRxiv.
[30] Francisco J. Sánchez-Rivera,et al. A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1. , 2019, Cancer discovery.
[31] A. Levine. The many faces of p53: something for everyone , 2019, Journal of molecular cell biology.
[32] J. Weinstein,et al. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. , 2019, Cell reports.
[33] S. Miyano,et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. , 2017, Blood.
[34] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Campbell,et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups , 2019, Leukemia.
[36] U. Platzbecker. Treatment of MDS. , 2019, Blood.
[37] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[38] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[39] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[40] D. Neuberg,et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.
[41] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[42] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[43] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[44] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[45] Magali Olivier,et al. TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.
[46] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..
[47] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[48] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[49] Christopher A. Miller,et al. The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.
[50] Deanna M. Church,et al. ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..
[51] Scott W. Lowe,et al. Putting p53 in Context , 2017, Cell.
[52] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[53] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[54] S. Fröhling,et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.